| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The cholesterol esterification enzyme acyl-CoA:cholesterol O-acyltransferase (ACAT) is strongly inhibited by RP-64477. RP-64477 was found to have in vitro inhibitory potency in tissue preparations derived from human cell cultures and a variety of animal species. There were no discernible species or tissue differences in the recorded IC50 values for animal tissues, which ranged from 6 to 283 nM. With IC50s of 503, 113, and 180 nM, respectively, RP-64477 demonstrates strong inhibitory activity in human hepatocyte (HepGZ), intestinal (CaCo-2), and monocyte (THP-1) cell lines. Up to 200 μM and 20 μM, respectively, of test concentrations showed no inhibitory activity against rat PCEH or LCAT [1].
|
|---|---|
| ln Vivo |
In rats fed cholesterol/cholic acid, the administration of RP-64477 (0.01% and 0.03% w/w in the diet) markedly decreased plasma cholesterol levels by 29% and 61%, respectively. Incorporating RP-64477 into the diet has no effect on food intake. During this time, animals given RP-64477 (10 and 30 mg/kg bid) showed noticeably decreased plasma cholesterol levels on days 4 and 7 when compared to animals given a diet high in cholesterol that were given a vehicle treatment. in contrast to the documented value. Following a 7-day dosage period, animals given 10 mg/kg of RP-64477 twice a day and 30 mg/kg of RP-64477 daily showed a 35% decrease in plasma cholesterol levels as compared to the cholesterol-fed controls. % and 53% [1].
|
| References |
| Molecular Formula |
C29H42N2O3S
|
|---|---|
| Molecular Weight |
498.720386981964
|
| Exact Mass |
498.291
|
| CAS # |
135239-65-5
|
| PubChem CID |
9870538
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
580.4±50.0 °C at 760 mmHg
|
| Flash Point |
304.8±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.563
|
| LogP |
8.73
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
35
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OZMWNRSILHTVFV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H42N2O3S/c1-4-6-8-9-10-11-12-13-21-34-25-17-14-23(15-18-25)29(33)31-26-22-24(16-19-27(26)35-3)28(32)30-20-7-5-2/h14-19,22H,4-13,20-21H2,1-3H3,(H,30,32)(H,31,33)
|
| Chemical Name |
N-butyl-3-[(4-decoxybenzoyl)amino]-4-methylsulfanylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~16.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0051 mL | 10.0257 mL | 20.0513 mL | |
| 5 mM | 0.4010 mL | 2.0051 mL | 4.0103 mL | |
| 10 mM | 0.2005 mL | 1.0026 mL | 2.0051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
